辛伐他汀对原发性高胆固醇血症患者hs-CRP、vWF的影响

The Effects of Simvastatin on High Sensitivity C-reactive Protein and Von Willebrand Factor in Patients with Primary Hypercholesterolemia

目的探讨辛伐他汀对原发性高胆固醇血症(HC)患者高敏C反应蛋白(hs-CRP)、血管假性血友病因子(vWF)的影响。方法选择HC患者48例,每晚口服辛伐他汀20 mg,分别于治疗前、治疗后4、8周进行hs-CRP、vWF、血脂等指标的测定;另选20例健康体检者对照。结果辛伐他汀治疗前后HC患者血清总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白胆固醇(LDL-C)含量显著下降(P<0.05),高密度胆固醇(HDL-C)含量升高(P<0.05)。HC患者血清、hs-CRP、血浆vWF含量较正常对照组显著升高(P<0.05)。辛伐他汀治疗4周后,hs-CRP显著降低(P<0.05);治疗8周后,vWF显著降低(P<0.05)。结论HC患者存在动脉粥样硬化发生发展的基础,辛伐他汀不但能有效调节血脂,而且能抑制炎症反应,修复血管内皮,从而稳定病情发展。

Objective To investigate the effects of simvastatin on high sensitivity C - reaction protein （hs- CRP） and yon Willebmnd Factor （vWF） in the patients with primary hypercholesterolemia. Methods 48 patients with primary hypercholesterolemia received simvastatin （20 nag QN）. Hs - CRP.vWF.lipidemia were mersured at beginning and after 4.8 weeks treatment. Compared with those in 20 heathy subjects. Results Before treatment the level of hs - CRP and vWF were significantly higher than that of healthy subjects （ P 〈 0.05）. TC.TG.LDL and hs - CRP were decreased significantly after 4 week of simvastatin treatment （ P 〈 0.05）. The level of HDL was also increased （ P 〉 0.05）. The level of vWF was decreasd significantly after 8 weeks of treatment （ P 〈 0.05）. Conclusion There are the foundationof atherosclerosis in patients with hyperlipidemia. Simvastatin treatment not only decreaes the levels of lipidemia, but also lower inflammatory reaction and improve effectively endothelial function.